XML 69 R58.htm IDEA: XBRL DOCUMENT v3.25.4
OPERATING SEGMENT (Details)
 12 Months Ended
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
SEGMENT INFORMATION    
Number of operating segments | segment 1  
Number of reportable segments | segment 1  
Research and development:    
General and administrative $ 11,481,083 $ 25,641,452
Segment and consolidated net loss 21,791,037 44,581,446
Single reportable segment    
Research and development:    
Phase 2 study in WM 1,308,000 7,422,000
Phase 1 study in pediatric tumors 1,345,000 3,040,000
Phase 1 study in triple negative breast cancer 933,000  
Manufacturing and related costs 4,220,000 10,582,000
Pre-clinical projects costs 823,000 228,000
General research and development costs 2,870,000 4,864,000
General and administrative 11,481,000 25,641,000
Other segment items (1,189,000) (7,196,000)
Segment and consolidated net loss $ 21,791,000 $ 44,581,000
Other segment items, description Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income. Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income.